NESS ZIONA, Israel, Sept. 30, 2019 /PRNewswire/ — BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced that BiomX’s Chief Executive Officer, Jonathan Solomon, will present at the Cantor Fitzgerald Global Healthcare Conference in New York on Wednesday, October 2nd, at 8:55am ET.
A webcast of the presentation will be available on the News and Events page of the company’s website at http://www.biomx.com/news/. A replay of the webcast will be available approximately two hours after the event and archived on the website for 90 days.
About BiomX
BiomX is a preclinical stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
On July 17th, 2019 BiomX announced that it has entered into a definitive agreement for a business combination with Chardan Healthcare Acquisition Corp. (NYSE: CHAC, “CHAC”), a special purpose acquisition company (“SPAC”) sponsored by affiliates of Chardan Capital Markets LLC (“Chardan”).
Media contact
MacDougall
Shai Biran, Ph.D.
Direct: +1-781-235-3060
sbiran@macbiocom.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/biomx-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-300926579.html
SOURCE BiomX Ltd.
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people…
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary…
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median…
Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV)…
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal…
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="103px" width="400px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
